In vivo and in vitro activity of a bis-arylidenecyclo-alkanone against fluconazole-susceptible and -resistant isolates of Candida albicans

Nívea Pereira de Sá, Lídia Fátima José de Paula, Larissa Ferreira Finamore Lopes, Lana Ivone Barreto Cruz, Thelma Tirone Silvério Matos, Cleudiomar Inácio Lino, Renata Barbosa de Oliveira, Elaine Maria de Souza-Fagundes, Beth Burgwyn Fuchs, Eleftherios Mylonakis, Susana Johann

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Objectives: Candida albicans is a commensal organism and opportunistic pathogen associated both with superficial (mucosal and cutaneous) and systemic infections. Extensive use of antifungal agents has led to reduced susceptibility to the few existing drugs, which has encouraged the search for novel antifungal agents. Therefore, the present study investigated the antifungal activity of 2,6-bis[(E)-(4-pyridyl)methylidene]cyclohexanone (PMC) against C. albicans. Methods: The in vitro activity of PMC was evaluated against C. albicans. Additionally, an invertebrate infection model in Caenorhabditis elegans as well as two infected murine models of oral and systemic candidiasis were used to determine the antifungal efficacy of PMC in vivo. Results: Minimum inhibitory concentrations (MICs) of PMC ranged from 4–32 μg/mL against nine clinical and two reference C. albicans isolates. Interestingly, PMC inhibited filamentation in vitro at subinhibitory concentrations similar to fluconazole. PMC also showed low toxicity against murine macrophages and human erythrocytes. In the invertebrate infection model, PMC was efficient in prolonging survival of C. elegans infected with C. albicans SC5314. Treatment with PMC was efficient both in murine models of systemic and oral candidiasis and was similar to that observed with conventional drug treatments (nystatin and fluconazole). Conclusions: The results of this study indicate the therapeutic potential of PMC as it was able to inhibit filamentation of C. albicans in vitro. These alterations to the fungi by PMC resulted in a reduction of oral and systemic infection in mice. In conclusion, we present promising evidence of the anticandidal activity of PMC in vitro and in vivo.

Original languageEnglish (US)
Pages (from-to)287-293
Number of pages7
JournalJournal of Global Antimicrobial Resistance
StatePublished - Sep 2018


  • Antifungal
  • Bis-arylidenecyclo-alkanone
  • Candida albicans
  • Murine model

ASJC Scopus subject areas

  • Microbiology
  • Immunology and Allergy
  • Immunology
  • Microbiology (medical)


Dive into the research topics of 'In vivo and in vitro activity of a bis-arylidenecyclo-alkanone against fluconazole-susceptible and -resistant isolates of Candida albicans'. Together they form a unique fingerprint.

Cite this